• PDF / 125,670 Bytes
• 7 Pages / 598 x 842 pts Page_size
• 18 Downloads / 184 Views

DOWNLOAD

REPORT

---

UPDATE

© 2008 Adis Data Information BV. All rights reserved.

Journal Watch Contents 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17.

Optimizing Therapy with Antibacterial Agents: Use of Pharmacokinetic-Pharmacodynamic Principles in Pediatrics . . . . . . . . . . . 59 Economic Evidence at the Local Level: Options for Making it More Useful . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59 Intelligent Risk Communication: Can it be Improved? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60 Biotherapeutics in the Era of Biosimilars: What Really Matters is Patient Safety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60 Biosimilar Drugs: Concerns and Opportunities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60 NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors: Was the Right Question Posed? Were the Best Tools Used? . . . . 60 Cardiac Repolarisation and Drug Regulation: Assessing Cardiac Safety 10 Years after the CPMP Guidance . . . . . . . . . . . . . . . . . 61 Methods for Causality Assessment of Adverse Drug Reactions: A Systematic Review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61 Antiarrhythmics: Elimination and Dosage Considerations in Hepatic Impairment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62 The Last Decade of Italian Pharmaceutical Policy: Instability or Consolidation? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62 Data Resources for Investigating Drug Exposure during Pregnancy and Associated Outcomes: The General Practice Research Database (GPRD) as an Alternative to Pregnancy Registries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62 Anticancer Therapy Targeting Telomeres and Telomerase: Current Status . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63 Detection of Spironolactone-Associated Hyperkalaemia Following the Randomized Aldactone Evaluation Study (RALES) . . . . . 63 Role of P-Glycoprotein Inhibition for Drug Interactions: Evidence from In Vitro and Pharmacoepidemiological Studies . . . . . . . . . 64 Predicting Oral Clearance in Humans: How Close Can We Get with Allometry? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens: CD4+ T-Cell Count and Gender in Hepatitis C Seropositive and Seronegative Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 Dynamic Modelling of Infectious Diseases: An Application to the Economic Evaluation of Influenza Vaccination . . .